Patients with myelodysplastic/myeloproliferative neoplasms have higher rates of relapse following allogeneic hematopoietic cell transplantation compared to those with MDS: A Brazilian SBTMO/CIBMTR registry analysis
Certain bone marrow cancers relapse more after transplant than expected, clarifying who needs different post-treatment approaches.
This Brazilian SBTMO/CIBMTR registry analysis demonstrates that MDS/MPN overlap patients experience significantly higher rates of relapse after allogeneic HCT compared to MDS, establishing important prognostic and management implications for this challenging hematologic malignancy subgroup. The data support the need for alternative post-transplant strategies in MDS/MPN overlap syndromes.
What the study was
- Study design
- Registry-based observational study (SBTMO/CIBMTR)
- Population
- MDS/MPN overlap neoplasm patients undergoing allo-HCT, Brazilian registry
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Bone Marrow Transplantation
Why it surfaced
Registry-based clinical data on a poorly-studied hematologic entity (MDS/MPN overlap); higher relapse rates post-HCT inform transplant decision-making. Underserved Brazilian patient population.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.